Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hearing
Stephen David Hearing, Bristol GB
| Patent application number | Description | Published |
|---|---|---|
| 20090274691 | Use of CD25 binding molecules in steroid-resistant patients - A method is provided for treating the diseases autoimmune hepatitis, eczema, vasculitis, temporal arteritis, sarcoid and Crohn's disease, in a steroid-resistant or steroid-sensitive patient. The method comprises administering to the patient an effective amount of a CD25 binding molecule and a steroid. | 11-05-2009 |
Vincent Hearing, Leesburg, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20100317590 | REGULATION OF SKIN CHARACTERISTICS BY DICKKOPF1 (DKK1) - The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype. | 12-16-2010 |
Vincent J. Hearing, Clarksburg, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090022674 | COSMETIC OR DERMATOLOGICAL PREPARATIONS COMPRISING OLIGOPEPTIDES FOR LIGHTENING THE SKIN OF AGE MARKS AND/OR FOR PREVENTING TANNING OF THE SKIN, IN PARTICULAR TANNING OF THE SKIN CAUSED BY UV RADIATION - Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimeric or homo- or heterotrimeric or homo- or heterotetrameric oligopeptides, where these oligopeptides are based on a Structure Val-Val-Arg-Pro SEQ ID NO: 1 as homo- or heteromonomer. | 01-22-2009 |
Vincent J. Hearing, Leesburg, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20110269691 | Compositions and Methods for Treating Pigmentary Conditions and Melanoma - A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer. A method of sensitizing a melanoma cell to RA comprising administering to the subject an amount of SOX9 sufficient to decrease PRAME expression. A method of increasing p21 expression in a subject comprising administering to the subject an amount of SOX9 sufficient to increase p21 expression. Methods of screening for compounds that treat hypopigmentary conditions and/or melanoma are provided. | 11-03-2011 |